alexa Phase I Clinical Trial of Peptide Vaccination with KIF2
ISSN: 2165-7092

Pancreatic Disorders & Therapy
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Phase I Clinical Trial of Peptide Vaccination with KIF20A and VEGFR1 Epitope Peptides in Patients with Advanced Pancreatic Cancer

*Junko Kato, Akihito Nagahara, Tomohiro Kodani, Yoshie Higashihara, Yuji Matsumura, Taro Osada, Takashi Yoshizawa, Masafumi Suyama, and Sumio Watanabe
Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan
Corresponding Author : Junko Kato
Juntendo University School of Medicine
Hongo, Bunkyo-ku, Tokyo, Japan
Tel: +81-3-5802-1060
Fax: +81-3-3813-8862
E-mail: [email protected]
Received November 08, 2011; Accepted December 21, 2011; Published January18, 2012
Citation: Kato J, Nagahara A, Kodani T, Higashihara Y,Matsumura Y, et al. (2012) Phase I Clinical Trial of Peptide Vaccination with KIF20A and VEGFR1 Epitope Peptides in Patients with Advanced Pancreatic Cancer. Pancreatic Dis Ther 2:102. doi:10.4172/2165-7092.1000102
Copyright: © 2012 Kato J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


We investigated the safety of peptide vaccination with HLA-A2402-restricted KIF20A and VEGFR1 epitope peptides in patients with advanced pancreatic cancer that was refractory to chemotherapy. This was a prospective nonrandomized, single-arm, phase I clinical trial with a fixed 2-mg dose of KIF20A and VEGFR1 peptides for patients with advanced unresectable pancreatic cancer. We determined the HLA genotype of the subjects after enrollment, results of which were held by the evaluative committee and kept from both patients and investigators until completion of the study. The primary endpoint was safety of the peptide vaccination with secondary endpoints being the immunological responses and clinical outcome. We compared study endpoints between the HLA-A*2402-positive and HLA-A*2402- negative groups. KIF20A and VEGFR1 peptides were subcutaneously administered on days 1, 8, 15, and 22 within a 28-day treatment cycle. Nineteen patients diagnosed with unresectable pancreatic cancer were enrolled from May 2009 to January 2010 at our Hospital. Twelve of the 19 patients received 4 or more vaccinations (at least one course). No patient had a severe adverse event in relation to this treatment. Findings from evaluation of clinical responses after one course showed that 2 cases had stable disease and 10 progressive disease. The median overall survival time (MST) for the 12 patients was 5.3 months. In the HLA-A*2402-positive group and HLA-A*2402-negative group, the MST was 6.0 months and 2.3 months (p=0.0373), respectively. Results of this study showed that vaccination with KIF20A and VEGFR1 peptides was a safe treatment, might be a promising treatment. This trial was registered with University Hospital Medical Information Network (UMIN) number UMIN000002022.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version